Imunon annual operating income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Operating Income Growth & History (IMNN)
Imunon's operating income was −$14.7M for fiscal 2025.
View full Imunon company overviewImunon annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$14.7M | $4.5M | — |
| 2024 | 2024-12-31 | −$19.1M | $1.9M | — |
| 2023 | 2023-12-31 | −$21.0M | $3.9M | — |
| 2022 | 2022-12-31 | −$24.9M | −$3.9M | — |
| 2021 | 2021-12-31 | −$21.0M | −$2.5M | — |
| 2020 | 2020-12-31 | −$18.5M | $2.1M | — |
| 2019 | 2019-12-31 | −$20.6M | $499,571 | — |
| 2018 | 2018-12-31 | −$21.1M | −$2.6M | — |
| 2017 | 2017-12-31 | −$18.5M | $2.2M | — |
| 2016 | 2016-12-31 | −$20.6M | $196,973 | — |
| 2015 | 2015-12-31 | −$20.8M | $3.9M | — |
| 2014 | 2014-12-31 | −$24.7M | −$9.3M | — |
| 2013 | 2013-12-31 | −$15.4M | $6.7M | — |
| 2012 | 2012-12-31 | −$22.1M | $876,052 | — |
| 2011 | 2011-12-31 | −$23.0M | −$3.4M | — |
| 2010 | 2010-12-31 | −$19.6M | — | — |
Imunon quarterly operating income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.8M | −$23,682 | — |
| Q1 2026 | 2026-03-31 | −$4.3M | −$161,253 | — |
| Q4 2025 | 2025-12-31 | −$4.3M | −$115,521 | — |
| Q3 2025 | 2025-09-30 | −$3.5M | $1.5M | — |
| Q2 2025 | 2025-06-30 | −$2.8M | $2.2M | — |
| Q1 2025 | 2025-03-31 | −$4.1M | $866,147 | — |
| Q4 2024 | 2024-12-31 | −$4.1M | $1.8M | — |
| Q3 2024 | 2024-09-30 | −$5.0M | −$1.1M | — |
| Q2 2024 | 2024-06-30 | −$5.0M | $460,934 | — |
| Q1 2024 | 2024-03-31 | −$5.0M | $673,004 | — |
| Q4 2023 | 2023-12-31 | −$6.0M | $959,124 | — |
| Q3 2023 | 2023-09-30 | −$3.9M | $2.3M | — |
| Q2 2023 | 2023-06-30 | −$5.5M | $503,986 | — |
| Q1 2023 | 2023-03-31 | −$5.7M | $157,527 | — |
| Q4 2022 | 2022-12-31 | −$6.9M | −$1.4M | — |
| Q3 2022 | 2022-09-30 | −$6.2M | −$1.1M | — |
| Q2 2022 | 2022-06-30 | −$6.0M | −$906,869 | — |
| Q1 2022 | 2022-03-31 | −$5.8M | −$458,633 | — |
| Q4 2021 | 2021-12-31 | −$5.5M | −$697,008 | — |
| Q3 2021 | 2021-09-30 | −$5.1M | −$901,976 | — |
| Q2 2021 | 2021-06-30 | −$5.1M | −$304,405 | — |
| Q1 2021 | 2021-03-31 | −$5.4M | −$617,389 | — |
| Q4 2020 | 2020-12-31 | −$4.8M | −$46,194 | — |
| Q3 2020 | 2020-09-30 | −$4.2M | $1.2M | — |
| Q2 2020 | 2020-06-30 | −$4.8M | $802,761 | — |
| Q1 2020 | 2020-03-31 | −$4.8M | $94,568 | — |
| Q4 2019 | 2019-12-31 | −$4.7M | $2,701 | — |
| Q3 2019 | 2019-09-30 | −$5.4M | −$1.4M | — |
| Q2 2019 | 2019-06-30 | −$5.6M | $2.4M | — |
| Q1 2019 | 2019-03-31 | −$4.9M | −$579,419 | — |
| Q4 2018 | 2018-12-31 | −$4.8M | $103,473 | — |
| Q3 2018 | 2018-09-30 | −$4.0M | $375,877 | — |
| Q2 2018 | 2018-06-30 | −$8.0M | −$3.6M | — |
| Q1 2018 | 2018-03-31 | −$4.3M | $537,294 | — |
| Q4 2017 | 2017-12-31 | −$4.9M | $280,004 | — |
| Q3 2017 | 2017-09-30 | −$4.4M | $1.2M | — |
| Q2 2017 | 2017-06-30 | −$4.4M | $342,580 | — |
| Q1 2017 | 2017-03-31 | −$4.8M | $360,298 | — |
| Q4 2016 | 2016-12-31 | −$5.1M | −$186,955 | — |
| Q3 2016 | 2016-09-30 | −$5.6M | −$1.4M | — |
| Q2 2016 | 2016-06-30 | −$4.7M | $503,865 | — |
| Q1 2016 | 2016-03-31 | −$5.2M | $1.2M | — |
| Q4 2015 | 2015-12-31 | −$4.9M | $1.5M | — |
| Q3 2015 | 2015-09-30 | −$4.2M | $2.4M | — |
| Q2 2015 | 2015-06-30 | −$5.2M | $1.2M | — |
| Q1 2015 | 2015-03-31 | −$6.4M | −$1.2M | — |
| Q4 2014 | 2014-12-31 | −$6.4M | −$3.2M | — |
| Q3 2014 | 2014-09-30 | −$6.7M | −$3.1M | — |
| Q2 2014 | 2014-06-30 | −$6.4M | −$2.6M | — |
| Q1 2014 | 2014-03-31 | −$5.2M | −$435,119 | — |
| Q4 2013 | 2013-12-31 | −$3.3M | $1.9M | — |
| Q3 2013 | 2013-09-30 | −$3.5M | $1.4M | — |
| Q2 2013 | 2013-06-30 | −$3.8M | $1.9M | — |
| Q1 2013 | 2013-03-31 | −$4.8M | $1.5M | — |
| Q4 2012 | 2012-12-31 | −$5.2M | $1.2M | — |
| Q3 2012 | 2012-09-30 | −$5.0M | $1.9M | — |
| Q2 2012 | 2012-06-30 | −$5.7M | $538,482 | — |
| Q1 2012 | 2012-03-31 | −$6.3M | −$2.7M | — |
| Q4 2011 | 2011-12-31 | −$6.4M | — | — |
| Q3 2011 | 2011-09-30 | −$6.8M | −$1.7M | — |
| Q2 2011 | 2011-06-30 | −$6.2M | −$1.8M | — |
| Q1 2011 | 2011-03-31 | −$3.6M | — | — |
| Q3 2010 | 2010-09-30 | −$5.2M | — | — |
| Q2 2010 | 2010-06-30 | −$4.5M | — | — |
Imunon operating income trends
Over the last five fiscal years, Imunon's operating income increased from −$18.5M to −$14.7M, a change of $3.8M. The latest reported quarter, Q2 2026, shows −$2.8M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...